What it is
Alprazolam is a triazolo benzodiazepine with rapid absorption and an intermediate half-life (11–16 hours). It is effective in acute anxiety and panic disorder and starts working in 15–30 minutes, which makes it popular, but it also carries a high risk of dependence.
Guidelines limit its use to short periods —the product information sets a maximum of weeks, withdrawal included— and as a bridge while the core treatment (an SSRI and psychotherapy) takes effect. It is a prescription medicine and is controlled because of its risk of misuse.
Mechanism of action
It enhances:
- GABAergic effects: it binds to GABA-A receptors, increasing their affinity for GABA
- It hyperpolarises neurones, reducing excitability
- Anxiolytic, sedative, muscle-relaxant and anticonvulsant (all through GABA)
At the counter
When to recommend it
- Acute panic attack
- Severe acute anxiety
- Agoraphobia with panic attacks
- As a bridge when starting an SSRI, for a few weeks
When not to
- History of alcohol or drug misuse (caution)
- Pregnancy: avoid, especially in the first trimester and near the end (neonatal withdrawal syndrome)
- Untreated sleep apnoea
- Severe respiratory failure or myasthenia gravis
- As the only treatment for depression
Warnings
- Important Dependence and tolerance: they develop quickly (2–4 weeks). High risk of misuse. Severe withdrawal if stopped suddenly.
- Important Cognitive effects: anterograde amnesia (not remembering what happened after taking it), disinhibition, risky behaviour.
- Caution Drowsiness, unsteadiness, confusion.
- Caution Paradoxical reaction: in some people (especially young people and older people), increased anxiety or agitation.
Pharmacokinetics
- Absorption
- Very rapid and complete absorption. Bioavailability of 80–90%. Onset at 15–30 minutes, peak at 1–2 hours.
- Distribution
- Rapid distribution into the CNS (fat-soluble). Protein binding of 80%. It crosses the placenta and the blood–brain barrier.
- Metabolism
- Hepatic metabolism by conjugation and oxidation (CYP3A4). It produces active metabolites (α-hydroxy-alprazolam).
- Elimination
- Renal elimination of metabolites. Half-life of 12–15 hours, with active metabolites extending the effect.
Alprazolam vs sertraline
| Aspect | Alprazolam | Sertraline (SSRI) |
|---|---|---|
| Onset of effect | Fast (15–30 min) | Slow (2–4 weeks) |
| Dependence | High risk | No |
| Long-term use | NOT recommended | Recommended |
| Acute anxiety | Excellent | Not effective at first |
| Treatment role | Bridge (a few weeks) | Long-term maintenance |
Alprazolam only for short periods. Sertraline for chronic anxiety. At the start they can be combined, on medical advice.
Self-assessment
Three questions. When you check your answers you will see the explanation for each one.
-
Alprazolam produces tolerance within a few weeks and physical dependence quickly. Long-term use is not recommended.
-
An SSRI is the long-term core treatment. Benzodiazepines are a temporary bridge while the SSRI takes effect.
-
Benzodiazepine withdrawal can be serious and prolonged. It is always withdrawn gradually, following the doctor's schedule over weeks.
Training content. It does not replace the summary of product characteristics or clinical judgement.